CARM1 and breast carcinoma: More importantly, there is no additive effect upon combining CARM1-KO with SKI-73 (6a) treatment, underlying the fact that the two orthogonal approaches target the commonly shared pathway(s) that are essential for the invasion of breast cancer cells.